Results 151 to 160 of about 1,231 (164)

CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations

International Journal of Pharmaceutics, 2010
Mucosal administration of vaccines has many advantages compared to parenteral vaccination. Needle-free mucosal vaccination would be easily applicable, target the vaccine to the entry point of many pathogens, and reduce the risk of infection with other pathogens during vaccination as compared to invasive methods.
Dennis Christensen, Camilla Foged, Ida Rosenkrands   +2 more
exaly   +4 more sources

Designing CAF-adjuvanted dry powder vaccines: Spray drying preserves the adjuvant activity of CAF01

Journal of Controlled Release, 2013
Dry powder vaccine formulations are highly attractive due to improved storage stability and the possibility for particle engineering, as compared to liquid formulations. However, a prerequisite for formulating vaccines into dry formulations is that their physicochemical and adjuvant properties remain unchanged upon rehydration. Thus, we have identified
Pall Thor Ingvarsson, Signe Tandrup Schmidt, Dennis Christensen   +2 more
exaly   +5 more sources

Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder

Vaccine, 2018
Liquid vaccine dosage forms have limited stability and require refrigeration during their manufacture, distribution and storage. In contrast, solid vaccine dosage forms, produced by for example spray drying, offer improved storage stability and reduced dependence on cold-chain facilities.
Aneesh Thakur, Pall Thor Ingvarsson, Signe Tandrup Schmidt   +2 more
exaly   +4 more sources

Design of Gadoteridol-Loaded Cationic Liposomal Adjuvant CAF01 for MRI of Lung Deposition of Intrapulmonary Administered Particles

Molecular Pharmaceutics, 2019
Designing effective and safe tuberculosis (TB) subunit vaccines for inhalation requires identification of appropriate antigens and adjuvants and definition of the specific areas to target in the lungs. Magnetic resonance imaging (MRI) enables high spatial resolution, but real-time anatomical and functional MRI of lungs is challenging. Here, we describe
Aneesh Thakur, Fabrice Rose, Shaquib Rahman Ansari   +2 more
exaly   +4 more sources

Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01

Vaccine, 2011
Therapeutic immunization of HIV-1-infected individuals with or without anti-retroviral therapy is a new promising disease prevention. To induce a new cytotoxic T(CD8) lymphocyte (CTL) immunity during chronic HIV-1 infection 15 infrequently targeted but conserved HLA-supertype binding CTL epitopes from Gag, Pol, Nef, Env, Vpu and Vif were identified ...
Anders Fomsgaard, Peter Bang, Íngrid Kromann   +2 more
exaly   +3 more sources

Development and Evaluation of CAF01

2017
Dennis Christensen
exaly   +2 more sources

Pulmonary Administration of the Liposome-Based Adjuvant CAF01: Effect of Surface Charge on Mucosal Adjuvant Function

Molecular Pharmaceutics, 2022
Mucosal surfaces of the lungs represent a major site of entry for airborne pathogens, and pulmonary administration of vaccines is an attractive strategy to induce protective mucosal immunity in the airways. Recently, we demonstrated the potential of pulmonary vaccination with the tuberculosis subunit antigen H56 adjuvanted with the cationic liposomal ...
Olivia Amanda Oest Müllertz, Peter Andersen, Dennis Christensen, Camilla Foged, Aneesh Thakur   +4 more
openaire   +3 more sources

Immunity by formulation design: Induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method

Journal of Controlled Release, 2011
The combination of nucleic acid-based Toll-like receptor (TLR)-3 or TLR9 agonists and cationic liposomes constitutes an effective vaccine adjuvant approach for eliciting CD8+ T-cell responses. However, complexing cationic liposomes and oppositely charged oligonucleotides generally results in highly unstable and heterogeneous formulations with limited ...
Nordly, Pernille Juul, Rose, Fabrice, Christensen, Dennis, Nielsen, Hanne Mørck, Andersen, Peter, Agger, Else Marie, Foged, Camilla   +6 more
openaire   +3 more sources

Vaccination with a Hybrid 1 (H1) fusion protein combined with a liposomal adjuvant (CAF01) induced antigen specific T-cells 3 years post vaccination in a human clinical trial. (VAC7P.971)

The Journal of Immunology, 2014
Abstract Approximately one third of the world’s population is infected with Mycobacterium tuberculosis. Developing novel vaccines to protect against pulmonary tuberculosis is a public health priority. In this study, a Hybrid 1 (H1) subunit vaccine containing a recombinant fusion protein of Ag85B and ESAT-6 was paired with a two-component
Dawn Henson, Jaap van Dissel, Simone Joosten, Andrew Graves, Søren Hoff, Darius Soonawala, Corine Prines, Birgit Thierry-Carstensen, Lars Andreasen, Adriette de Visser, Else Agger, Tom Ottenhoff, Ingrid Kromann, Peter Andersen, David Hokey   +14 more
openaire   +1 more source

Sublingual Boosting with a Novel Mucoadhesive Thermogelling Hydrogel Following Parenteral CAF01 Priming as a Strategy Against Chlamydia trachomatis (Adv. Healthcare Mater. 11/2022)

Advanced Healthcare Materials, 2022
Lorena Garcia‐del Rio, Patricia Diaz‐Rodriguez, Gabriel Kristian Pedersen, Dennis Christensen, Mariana Landin   +4 more
openaire   +1 more source